

Supplementary Materials for
Consolidated Financial Results
for the 1st Quarter of Fiscal Year 2012. 12



CHUGAI PHARMACEUTICAL CO., LTD.



A member of the Roche group

- Notes: 1. Portions of this report that refer to performance forecasts or any other future events are believed to be reasonable under information available at the time of the forecasts. Actual results may materially differ from these forecasts due to potential risks and uncertainties.
2. Amounts shown in Financial Highlights, Statements of Revenues, Balance Sheets, Cash Flows and Capital Expenditures of this report are rounded to the nearest 0.1 billion yen. Variance and % are calculated based on the amounts shown.
3. Exchange rates used for each period are as follows.

(Yen)

Fx rates	FY2009	FY2010	FY2011				FY2012				Forecast
	1-12	1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12	FY2012
	(Full-year)	(YTD)	(YTD)	(YTD)	(YTD)	(YTD)	(YTD)	(YTD)	(YTD)	(YTD)	(Full-year)
	average	average	average	average	average	average	average	average	average	average	forecast
CHF	86.20	84.17	87.30	90.38	91.62	89.86	86.01	—	—	—	85.00
EUR	130.10	116.32	112.36	114.86	113.25	110.92	103.91	—	—	—	109.00
USD	93.60	87.81	82.23	81.93	80.55	79.75	79.26	—	—	—	82.00

Financial Highlights (YTD)

(Billions of Yen)

	FY2009	FY2010	FY2011				FY2012								Forecast			
															FY2012			
			1-3	1-6	1-9	1-12	1-3	Change (%)	1-6	Change (%)	1-9	Change (%)	1-12	Change (%)	1-6	Change (%)	1-12	Change (%)
	1-12	1-12	YTD	YTD	YTD	YTD	YTD		YTD		YTD		YTD		Half-year		Full-year	
Revenues	428.9	379.5	85.7	181.9	276.0	373.5	90.3	+5.4	—	—	—	—	—	—	195.5	+7.5	418.5	+12.0
Sales	419.1	375.6	80.4	174.8	267.5	363.6	86.8	+8.0	—	—	—	—	—	—	189.5	+8.4	403.7	+11.0
excl. Tamiflu	342.9	357.4	76.2	170.2	261.2	354.9	79.0	+3.7	—	—	—	—	—	—	181.2	+6.5	394.1	+11.0
Tamiflu	76.2	18.2	4.2	4.6	6.3	8.7	7.8	+85.7	—	—	—	—	—	—	8.3	+80.4	9.6	+10.3
Ordinary sales	36.2	1.6	3.7	4.1	4.1	5.4	7.5	+102.7	—	—	—	—	—	—	8.0	+95.1	9.3	+72.2
Govt. stockpile etc.	40.0	16.6	0.5	0.5	2.2	3.3	0.4	(20.0)	—	—	—	—	—	—	0.3	(40.0)	0.3	(90.9)
Other operating revenues	9.8	3.9	5.3	7.2	8.5	9.9	3.5	(34.0)	—	—	—	—	—	—	6.0	(16.7)	14.8	+49.5
Cost of sales	192.9	162.4	35.1	74.5	115.4	157.5	39.6	+12.8	—	—	—	—	—	—	—	—	178.5	+13.3
(% of Sales)	46.0	43.2	43.7	42.6	43.1	43.3	45.6	—	—	—	—	—	—	—	—	—	44.2	—
Gross profit	236.1	217.1	50.6	107.4	160.7	216.0	50.6	+0.0	—	—	—	—	—	—	—	—	240.0	+11.1
(% of Revenues)	55.0	57.2	59.0	59.0	58.2	57.8	56.0	—	—	—	—	—	—	—	—	—	57.3	—
SG&A (excl. R&D) expenses	98.2	96.2	22.0	45.3	69.4	97.7	21.0	(4.5)	—	—	—	—	—	—	—	—	100.0	+2.4
(% of Revenues)	22.9	25.3	25.7	24.9	25.1	26.2	23.3	—	—	—	—	—	—	—	—	—	23.9	—
R&D expenses	55.3	54.7	13.0	26.9	41.2	55.9	13.1	+0.8	—	—	—	—	—	—	—	—	60.0	+7.3
(% of Revenues)	12.9	14.4	15.2	14.8	14.9	15.0	14.5	—	—	—	—	—	—	—	—	—	14.3	—
Operating income	82.6	66.2	15.6	35.2	50.0	62.4	16.6	+6.4	—	—	—	—	—	—	36.5	+3.7	80.0	+28.2
(% of Revenues)	19.3	17.4	18.2	19.4	18.1	16.7	18.4	—	—	—	—	—	—	—	18.7	—	19.1	—
Non-operating income	9.4	2.4	2.1	1.3	3.3	2.3	1.1	(47.6)	—	—	—	—	—	—	—	—	—	—
Non-operating expenses	1.6	3.5	1.0	0.4	2.2	1.2	1.5	+50.0	—	—	—	—	—	—	—	—	—	—
Ordinary income	90.4	65.1	16.7	36.2	51.1	63.6	16.3	(2.4)	—	—	—	—	—	—	37.0	+2.2	80.5	+26.6
(% of Revenues)	21.1	17.2	19.5	19.9	18.5	17.0	18.1	—	—	—	—	—	—	—	18.9	—	19.2	—
Extraordinary gain	0.3	0.6	—	—	0.0	0.0	0.0	—	—	—	—	—	—	—	—	—	—	—
Extraordinary loss	1.3	0.0	7.1	7.6	9.1	6.5	0.0	(100.0)	—	—	—	—	—	—	—	—	—	—
Income before income taxes etc.	89.4	65.7	9.6	28.6	42.0	57.1	16.3	+69.8	—	—	—	—	—	—	—	—	—	—
(% of Revenues)	20.8	17.3	11.2	15.7	15.2	15.3	18.1	—	—	—	—	—	—	—	—	—	—	—
Net income	56.6	41.4	5.0	17.1	27.1	35.2	9.3	+86.0	—	—	—	—	—	—	22.0	+28.7	49.0	+39.2
(% of Revenues)	13.2	10.9	5.8	9.4	9.8	9.4	10.3	—	—	—	—	—	—	—	11.3	—	11.7	—

Financial Highlights (QTR)

(Billions of Yen)

	FY2009	FY2010	FY2011				FY2012								Forecast			
															FY2012			
			1-3	4-6	7-9	10-12	1-3	Change (%)	4-6	Change (%)	7-9	Change (%)	10-12	Change (%)	1-6	Change (%)	7-12	Change (%)
			Full-year	Full-year	QTR	QTR	QTR		QTR		QTR		QTR		1st Half		2nd Half	
Revenues	428.9	379.5	85.7	96.2	94.1	97.5	90.3	+5.4	—	—	—	—	—	—	195.5	+7.5	223.0	+16.4
Sales	419.1	375.6	80.4	94.4	92.7	96.2	86.8	+8.0	—	—	—	—	—	—	189.5	+8.4	214.2	+13.4
excl. Tamiflu	342.9	357.4	76.2	94.0	91.0	93.7	79.0	+3.7	—	—	—	—	—	—	181.2	+6.5	212.9	+15.3
Tamiflu	76.2	18.2	4.2	0.4	1.7	2.4	7.8	+85.7	—	—	—	—	—	—	8.3	+80.4	1.3	(68.3)
Ordinary sales	36.2	1.6	3.7	0.4	0.0	1.3	7.5	+102.7	—	—	—	—	—	—	8.0	+95.1	1.3	+0.0
Govt. stockpile etc.	40.0	16.6	0.5	—	1.7	1.1	0.4	(20.0)	—	—	—	—	—	—	0.3	(40.0)	—	(100.0)
Other operating revenues	9.8	3.9	5.3	1.8	1.4	1.3	3.5	(34.0)	—	—	—	—	—	—	6.0	(16.7)	8.8	+225.9
Cost of sales	192.9	162.4	35.1	39.4	40.8	42.1	39.6	+12.8	—	—	—	—	—	—	—	—	—	—
(% of Sales)	46.0	43.2	43.7	41.7	44.0	43.8	45.6	—	—	—	—	—	—	—	—	—	—	—
Gross profit	236.1	217.1	50.6	56.8	53.3	55.4	50.6	+0.0	—	—	—	—	—	—	—	—	—	—
(% of Revenues)	55.0	57.2	59.0	59.0	56.6	56.8	56.0	—	—	—	—	—	—	—	—	—	—	—
SG&A (excl. R&D) expenses	98.2	96.2	22.0	23.2	24.1	28.3	21.0	(4.5)	—	—	—	—	—	—	—	—	—	—
(% of Revenues)	22.9	25.3	25.7	24.1	25.6	29.0	23.3	—	—	—	—	—	—	—	—	—	—	—
R&D expenses	55.3	54.7	13.0	13.9	14.3	14.6	13.1	+0.8	—	—	—	—	—	—	—	—	—	—
(% of Revenues)	12.9	14.4	15.2	14.4	15.2	15.0	14.5	—	—	—	—	—	—	—	—	—	—	—
Operating income	82.6	66.2	15.6	19.6	14.8	12.4	16.6	+6.4	—	—	—	—	—	—	36.5	+3.7	43.5	+59.9
(% of Revenues)	19.3	17.4	18.2	20.4	15.7	12.7	18.4	—	—	—	—	—	—	—	18.7	—	19.5	—
Non-operating income	9.4	2.4	2.1	1.2	2.1	1.9	1.1	(47.6)	—	—	—	—	—	—	—	—	—	—
Non-operating expenses	1.6	3.5	1.0	1.4	2.0	1.8	1.5	+50.0	—	—	—	—	—	—	—	—	—	—
Ordinary income	90.4	65.1	16.7	19.5	14.9	12.5	16.3	(2.4)	—	—	—	—	—	—	37.0	+2.2	43.5	+58.8
(% of Revenues)	21.1	17.2	19.5	20.3	15.8	12.8	18.1	—	—	—	—	—	—	—	18.9	—	19.5	—
Extraordinary gain	0.3	0.6	—	—	0.0	0.0	0.0	—	—	—	—	—	—	—	—	—	—	—
Extraordinary loss	1.3	0.0	7.1	0.5	1.5	(2.6)	0.0	(100.0)	—	—	—	—	—	—	—	—	—	—
Income before income taxes etc.	89.4	65.7	9.6	19.0	13.4	15.2	16.3	+69.8	—	—	—	—	—	—	—	—	—	—
(% of Revenues)	20.8	17.3	11.2	19.8	14.2	15.6	18.1	—	—	—	—	—	—	—	—	—	—	—
Net income	56.6	41.4	5.0	12.1	10.0	8.1	9.3	+86.0	—	—	—	—	—	—	22.0	+28.7	27.0	+49.2
(% of Revenues)	13.2	10.9	5.8	12.6	10.6	8.3	10.3	—	—	—	—	—	—	—	11.3	—	12.1	—

Statements of Revenues (YTD)

(Billions of Yen)

		FY2009	FY2010	FY2011				FY2012								Forecast FY2012			
		1-12	1-12	1-3	1-6	1-9	1-12	1-3	Change (%)	1-6	Change (%)	1-9	Change (%)	1-12	Change (%)	1-6	Change (%)	1-12	Change (%)
		Full-year	Full-year	YTD	YTD	YTD	YTD	YTD		YTD		YTD		YTD		Half-year		Full-year	
Sales		419.1	375.6	80.4	174.8	267.5	363.6	86.8	+8.0	—	—	—	—	—	—	189.5	+8.4	403.7	+11.0
Excl. Tamiflu		342.9	357.4	76.2	170.2	261.2	354.9	79.0	+3.7	—	—	—	—	—	—	181.2	+6.5	394.1	+11.0
Domestic		309.3	324.4	70.2	150.9	227.8	315.3	68.1	(3.0)	—	—	—	—	—	—	160.8	+6.6	353.9	+12.2
Oncology field		123.7	141.2	31.0	67.9	101.5	141.9	32.7	+5.5	—	—	—	—	—	—	74.4	+9.6	165.4	+16.6
Avastin		34.9	52.6	12.5	26.4	40.2	56.4	13.4	+7.2	—	—	—	—	—	—	30.7	+16.3	68.8	+22.0
Herceptin		29.7	25.3	5.6	13.9	18.7	25.9	6.1	+8.9	—	—	—	—	—	—	12.7	(8.6)	27.3	+5.4
Rituxan		21.1	23.0	4.9	10.4	16.2	22.9	5.3	+8.2	—	—	—	—	—	—	11.3	+8.7	25.3	+10.5
Xeloda		6.6	10.7	2.3	4.9	7.4	10.0	2.4	+4.3	—	—	—	—	—	—	7.3	+49.0	16.8	+68.0
Neutrogen		11.3	10.4	1.8	4.1	6.6	9.4	1.8	+0.0	—	—	—	—	—	—	4.2	+2.4	9.7	+3.2
Tarceva		5.8	7.9	1.7	3.8	5.8	8.3	1.9	+11.8	—	—	—	—	—	—	3.6	(5.3)	8.2	(1.2)
Femara		2.4	3.2	0.8	1.7	2.6	3.6	0.8	+0.0	—	—	—	—	—	—	1.9	+11.8	4.3	+19.4
Kytril		8.6	5.5	0.8	1.7	2.5	3.4	0.6	(25.0)	—	—	—	—	—	—	1.6	(5.9)	3.1	(8.8)
Other products		3.3	2.5	0.5	1.0	1.5	2.1	0.4	(20.0)	—	—	—	—	—	—	1.0	+0.0	1.9	(9.5)
Bone and joint diseases field		57.6	62.6	14.0	30.4	47.2	66.2	13.6	(2.9)	—	—	—	—	—	—	31.4	+3.3	70.3	+6.2
Actemra		8.4	14.1	3.5	7.6	12.1	17.5	3.8	+8.6	—	—	—	—	—	—	7.8	+2.6	18.3	+4.6
Evista		17.9	18.7	3.8	8.4	13.2	18.5	3.4	(10.5)	—	—	—	—	—	—	8.0	(4.8)	16.9	(8.6)
Suvenyl		13.7	13.6	2.6	6.0	9.3	13.0	2.7	+3.8	—	—	—	—	—	—	6.8	+13.3	14.7	+13.1
Alfarol		13.6	12.3	2.6	5.4	8.2	11.2	2.2	(15.4)	—	—	—	—	—	—	3.8	(29.6)	8.0	(28.6)
Edirol *		—	—	—	0.6	0.8	1.3	0.6	—	—	—	—	—	—	—	2.7	+350.0	7.8	+500.0
Other products		3.9	4.0	1.5	2.4	3.6	4.6	0.9	(40.0)	—	—	—	—	—	—	2.1	(12.5)	4.6	+0.0
Renal diseases field		61.0	57.4	11.4	24.3	36.9	50.7	10.3	(9.6)	—	—	—	—	—	—	28.3	+16.5	62.7	+23.7
Mircera *		—	—	—	—	2.8	5.9	3.0	—	—	—	—	—	—	—	12.1	—	29.6	+401.7
Epogin		44.4	40.0	7.5	16.6	22.5	28.8	3.9	(48.0)	—	—	—	—	—	—	8.7	(47.6)	16.8	(41.7)
Oxarol		10.6	12.0	2.8	5.8	8.8	12.2	2.7	(3.6)	—	—	—	—	—	—	6.2	+6.9	13.5	+10.7
Renagel		5.3	4.9	1.1	1.7	2.3	3.1	0.6	(45.5)	—	—	—	—	—	—	1.1	(35.3)	2.3	(25.8)
Other products		0.7	0.5	0.1	0.2	0.4	0.7	0.1	+0.0	—	—	—	—	—	—	0.2	+0.0	0.5	(28.6)
Transplant, Immunology & Infectious diseases field		26.2	25.8	5.5	11.5	17.0	22.8	4.5	(18.2)	—	—	—	—	—	—	11.9	+3.5	25.6	+12.3
Pegasys		11.1	10.5	2.2	4.4	6.3	8.3	1.6	(27.3)	—	—	—	—	—	—	5.6	+27.3	12.1	+45.8
Copegus		4.9	4.5	0.9	1.9	2.6	3.3	0.5	(44.4)	—	—	—	—	—	—	1.2	(36.8)	2.7	(18.2)
CellCept		4.4	5.2	1.2	2.6	4.1	5.7	1.4	+16.7	—	—	—	—	—	—	2.7	+3.8	6.0	+5.3
Other products		5.8	5.7	1.2	2.6	4.0	5.5	1.1	(8.3)	—	—	—	—	—	—	2.4	(7.7)	4.7	(14.5)
Others field		40.9	37.4	8.3	16.8	25.2	33.8	6.9	(16.9)	—	—	—	—	—	—	14.8	(11.9)	30.0	(11.2)
Sigmart		14.7	13.0	2.7	5.7	8.3	11.1	2.2	(18.5)	—	—	—	—	—	—	4.7	(17.5)	9.8	(11.7)
Other products		26.3	24.4	5.6	11.0	16.9	22.6	4.8	(14.3)	—	—	—	—	—	—	10.1	(8.2)	20.1	(11.1)
Overseas		33.6	33.0	5.9	19.3	33.4	39.6	10.9	+84.7	—	—	—	—	—	—	20.4	+5.7	40.2	+1.5
Actemra		8.9	12.7	1.4	9.1	18.8	20.5	6.8	+385.7	—	—	—	—	—	—	12.3	+35.2	24.1	+17.6
Neutrogen		21.3	17.0	3.5	8.1	11.7	15.6	3.4	(2.9)	—	—	—	—	—	—	6.5	(19.8)	13.1	(16.0)
Sigmart		1.9	2.2	0.6	1.2	1.7	2.1	0.3	(50.0)	—	—	—	—	—	—	0.8	(33.3)	1.6	(23.8)
Other products		1.5	1.2	0.5	0.9	1.2	1.4	0.4	(20.0)	—	—	—	—	—	—	0.8	(11.1)	1.3	(7.1)
Tamiflu		76.2	18.2	4.2	4.6	6.3	8.7	7.8	+85.7	—	—	—	—	—	—	8.3	+80.4	9.6	+10.3
Ordinary sales		36.2	1.6	3.7	4.1	4.1	5.4	7.5	+102.7	—	—	—	—	—	—	8.0	+95.1	9.3	+72.2
Govt. stockpile etc.		40.0	16.6	0.5	0.5	2.2	3.3	0.4	(20.0)	—	—	—	—	—	—	0.3	(40.0)	0.3	(90.9)
Other operating revenues		9.8	3.9	5.3	7.2	8.5	9.9	3.5	(34.0)	—	—	—	—	—	—	6.0	(16.7)	14.8	+49.5
Revenues (total)		428.9	379.5	85.7	181.9	276.0	373.5	90.3	+5.4	—	—	—	—	—	—	195.5	+7.5	418.5	+12.0
Domestic		392.6	342.9	77.7	159.0	237.8	327.9	78.1	+0.5	—	—	—	—	—	—	171.6	+7.9	371.2	+13.2
Overseas		36.4	36.6	8.0	22.9	38.2	45.6	12.2	+52.5	—	—	—	—	—	—	23.9	+4.4	47.3	+3.7

Note: Edirol (launched in April 2011), Mircera (launched in July 2011)

Statements of Revenues (QTR)

(Billions of Yen)

			FY2011				FY2012								Forecast FY2012			
			FY2009		FY2010		1-3		4-6		7-9		10-12		1-6		7-12	
			1-12	1-12	1-12	1-12	1-3	Change (%)	4-6	Change (%)	7-9	Change (%)	10-12	Change (%)	1-6	Change (%)	7-12	Change (%)
			Full-year	Full-year	Full-year	Full-year	QTR	QTR	QTR	QTR	QTR	QTR	QTR	QTR	1st Half	2nd Half	1st Half	2nd Half
Sales			419.1	375.6	80.4	94.4	92.7	96.2	86.8	+8.0	—	—	—	—	189.5	+8.4	214.2	+13.4
Excl. Tamiflu			342.9	357.4	76.2	94.0	91.0	93.7	79.0	+3.7	—	—	—	—	181.2	+6.5	212.9	+15.3
Domestic			309.3	324.4	70.2	80.6	76.9	87.5	68.1	(3.0)	—	—	—	—	160.8	+6.6	193.1	+17.5
Oncology field			123.7	141.2	31.0	36.8	33.7	40.4	32.7	+5.5	—	—	—	—	74.4	+9.6	91.0	+23.0
Avastin			34.9	52.6	12.5	13.9	13.8	16.2	13.4	+7.2	—	—	—	—	30.7	+16.3	38.1	+27.0
Herceptin			29.7	25.3	5.6	8.3	4.8	7.2	6.1	+8.9	—	—	—	—	12.7	(8.6)	14.6	+21.7
Rituxan			21.1	23.0	4.9	5.5	5.8	6.7	5.3	+8.2	—	—	—	—	11.3	+8.7	14.0	+12.0
Xeloda			6.6	10.7	2.3	2.6	2.5	2.7	2.4	+4.3	—	—	—	—	7.3	+49.0	9.5	+86.3
Neutrogin			11.3	10.4	1.8	2.3	2.5	2.8	1.8	+0.0	—	—	—	—	4.2	+2.4	5.4	+1.9
Tarceva			5.8	7.9	1.7	2.1	2.0	2.4	1.9	+11.8	—	—	—	—	3.6	(5.3)	4.6	+2.2
Femara			2.4	3.2	0.8	0.9	0.9	1.0	0.8	+0.0	—	—	—	—	1.9	+11.8	2.4	+26.3
Kytril			8.6	5.5	0.8	0.9	0.8	0.9	0.6	(25.0)	—	—	—	—	1.6	(5.9)	1.5	(11.8)
Other products			3.3	2.5	0.5	0.5	0.5	0.5	0.4	(20.0)	—	—	—	—	1.0	+0.0	0.9	(10.0)
Bone and joint diseases field			57.6	62.6	14.0	16.4	16.8	19.0	13.6	(2.9)	—	—	—	—	31.4	+3.3	38.9	+8.7
Actemra			8.4	14.1	3.5	4.1	4.5	5.4	3.8	+8.6	—	—	—	—	7.8	+2.6	10.5	+6.1
Evista			17.9	18.7	3.8	4.6	4.8	5.3	3.4	(10.5)	—	—	—	—	8.0	(4.8)	8.9	(11.9)
Suvenyl			13.7	13.6	2.6	3.4	3.3	3.7	2.7	+3.8	—	—	—	—	6.8	+13.3	7.9	+12.9
Alfarol			13.6	12.3	2.6	2.8	2.8	3.1	2.2	(15.4)	—	—	—	—	3.8	(29.6)	4.2	(27.6)
Edirol			—	—	—	0.6	0.2	0.5	0.6	—	—	—	—	—	2.7	+350.0	5.0	+614.3
Other products			3.9	4.0	1.5	0.9	1.2	1.0	0.9	(40.0)	—	—	—	—	2.1	(12.5)	2.5	+8.7
Renal diseases field			61.0	57.4	11.4	12.9	12.6	13.8	10.3	(9.6)	—	—	—	—	28.3	+16.5	34.3	+29.9
Mircera			—	—	—	—	2.8	3.1	3.0	—	—	—	—	—	12.1	—	17.5	+196.6
Epogin			44.4	40.0	7.5	9.1	6.0	6.3	3.9	(48.0)	—	—	—	—	8.7	(47.6)	8.1	(33.6)
Oxarol			10.6	12.0	2.8	3.0	3.0	3.4	2.7	(3.6)	—	—	—	—	6.2	+6.9	7.3	+14.1
Renagel			5.3	4.9	1.1	0.7	0.6	0.7	0.6	(45.5)	—	—	—	—	1.1	(35.3)	1.2	(7.7)
Other products			0.7	0.5	0.1	0.1	0.2	0.3	0.1	+0.0	—	—	—	—	0.2	+0.0	0.2	(60.0)
Transplant, Immunology & Infectious diseases field			26.2	25.8	5.5	6.0	5.4	5.8	4.5	(18.2)	—	—	—	—	11.9	+3.5	13.6	+21.4
Pegasys			11.1	10.5	2.2	2.3	1.9	2.0	1.6	(27.3)	—	—	—	—	5.6	+27.3	6.6	+69.2
Copegus			4.9	4.5	0.9	1.0	0.7	0.7	0.5	(44.4)	—	—	—	—	1.2	(36.8)	1.5	+7.1
CellCept			4.4	5.2	1.2	1.4	1.4	1.6	1.4	+16.7	—	—	—	—	2.7	+3.8	3.3	+6.5
Other products			5.8	5.7	1.2	1.4	1.4	1.5	1.1	(8.3)	—	—	—	—	2.4	(7.7)	2.3	(20.7)
Others field			40.9	37.4	8.3	8.4	8.4	8.5	6.9	(16.9)	—	—	—	—	14.8	(11.9)	15.2	(10.6)
Sigmar			14.7	13.0	2.7	3.0	2.6	2.8	2.2	(18.5)	—	—	—	—	4.7	(17.5)	5.2	(3.7)
Other products			26.3	24.4	5.6	5.4	5.9	5.7	4.8	(14.3)	—	—	—	—	10.1	(8.2)	10.0	(13.8)
Overseas			33.6	33.0	5.9	13.4	14.1	6.3	10.9	+84.7	—	—	—	—	20.4	+5.7	19.8	(2.5)
Actemra			8.9	12.7	1.4	7.7	9.7	1.7	6.8	+385.7	—	—	—	—	12.3	+35.2	11.8	+3.5
Neutrogin			21.3	17.0	3.5	4.6	3.6	3.9	3.4	(2.9)	—	—	—	—	6.5	(19.8)	6.6	(12.0)
Sigmar			1.9	2.2	0.6	0.6	0.5	0.4	0.3	(50.0)	—	—	—	—	0.8	(33.3)	0.8	(11.1)
Other products			1.5	1.2	0.5	0.4	0.3	0.3	0.4	(20.0)	—	—	—	—	0.8	(11.1)	0.6	+0.0
Tamiflu			76.2	18.2	4.2	0.4	1.7	2.4	7.8	+85.7	—	—	—	—	8.3	+80.4	1.3	(68.3)
Ordinary sales			36.2	1.6	3.7	0.4	0.0	1.3	7.5	+102.7	—	—	—	—	8.0	+95.1	1.3	+0.0
Govt. stockpile etc.			40.0	16.6	0.5	—	1.7	1.1	0.4	(20.0)	—	—	—	—	0.3	(40.0)	—	(100.0)
Other operating revenues			9.8	3.9	5.3	1.8	1.4	1.3	3.5	(34.0)	—	—	—	—	6.0	(16.7)	8.8	+225.9
Revenues (total)			428.9	379.5	85.7	96.2	94.1	97.5	90.3	+5.4	—	—	—	—	195.5	+7.5	223.0	+16.4
Domestic			392.6	342.9	77.7	81.3	78.8	90.1	78.1	+0.5	—	—	—	—	171.6	+7.9	199.5	+18.1
Overseas			36.4	36.6	8.0	14.9	15.3	7.4	12.2	+52.5	—	—	—	—	23.9	+4.4	23.5	+3.5

Balance Sheets

	FY2009	FY2010	FY2011				FY2012					
	As of Dec. 31	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Mar. 31	vs. Mar. 31, 2011	vs. Dec. 31, 2011	As of Jun. 30	As of Sep. 30	As of Dec. 31
Cash and deposits	107.0	76.2	101.7	109.2	110.7	107.2	123.1	+21.4	+15.9	–	–	–
Trade notes and accounts receivable	121.6	113.4	94.6	105.8	98.4	110.9	94.6	0.0	(16.3)	–	–	–
Marketable securities	52.2	59.7	58.0	59.0	59.0	61.0	67.0	+9.0	+6.0	–	–	–
Inventories	92.6	104.9	108.5	110.4	115.7	105.0	101.2	(7.3)	(3.8)	–	–	–
Other current assets	37.9	32.3	39.7	27.6	33.9	35.4	35.1	(4.6)	(0.3)	–	–	–
Total Current assets	411.3	386.5	402.5	412.1	417.7	419.4	421.1	+18.6	+1.7	–	–	–
Property, plant and equipment	93.7	88.0	86.1	83.5	81.8	82.9	80.9	(5.2)	(2.0)	–	–	–
Intangible assets	3.2	2.4	2.3	2.4	2.1	2.0	1.9	(0.4)	(0.1)	–	–	–
Investments and other assets	32.3	31.2	29.3	31.3	32.8	29.2	28.5	(0.8)	(0.7)	–	–	–
thereof Investment securities	9.7	7.6	7.0	6.9	6.9	6.4	6.6	(0.4)	+0.2	–	–	–
Total Noncurrent Assets	129.2	121.5	117.8	117.3	116.7	114.1	111.4	(6.4)	(2.7)	–	–	–
Total Assets	540.5	508.0	520.3	529.4	534.4	533.5	532.5	+12.2	(1.0)	–	–	–
Trade notes and accounts payable	34.3	19.5	29.5	28.5	29.2	17.4	23.9	(5.6)	+6.5	–	–	–
Short-term loans and bonds	–	–	–	–	–	–	–	–	–	–	–	–
Other current liabilities	66.2	35.1	42.4	40.3	48.1	51.5	42.3	(0.1)	(9.2)	–	–	–
Total current liabilities	100.5	54.6	72.0	68.8	77.3	68.8	66.2	(5.8)	(2.6)	–	–	–
Long-term debt and bonds	–	–	–	–	–	–	–	–	–	–	–	–
Other noncurrent liabilities	5.4	4.0	5.3	5.3	5.4	5.6	5.5	+0.2	(0.1)	–	–	–
Total noncurrent liabilities	5.4	4.0	5.3	5.3	5.4	5.6	5.5	+0.2	(0.1)	–	–	–
Total liabilities	105.9	58.6	77.3	74.1	82.8	74.4	71.7	(5.6)	(2.7)	–	–	–
Common stock	73.0	73.0	73.0	73.0	73.0	73.0	73.0	–	–	–	–	–
Capital surplus	92.8	92.8	92.8	92.8	92.8	92.8	92.8	–	–	–	–	–
Retained earnings	308.0	327.6	320.1	332.2	331.4	339.5	338.0	+17.9	(1.5)	–	–	–
Treasury stock, at cost	(36.3)	(36.3)	(36.3)	(36.3)	(36.3)	(36.3)	(36.3)	0.0	0.0	–	–	–
Net unrealized gain or loss on securities	1.6	1.3	1.0	0.9	1.1	0.8	1.6	+0.6	+0.8	–	–	–
Deferred gains or losses on hedges	–	–	–	–	–	–	0.3	+0.3	+0.3	–	–	–
Foreign currency translation adjustments	(6.8)	(11.3)	(9.5)	(9.7)	(12.2)	(13.0)	(10.9)	(1.4)	+2.1	–	–	–
Subscription rights to shares	0.5	0.8	0.8	0.9	0.9	1.0	1.1	+0.3	+0.1	–	–	–
Minority interests	1.8	1.4	1.0	1.4	1.0	1.2	1.1	+0.1	(0.1)	–	–	–
Total net assets	434.7	449.4	443.0	455.3	451.6	459.1	460.8	+17.8	+1.7	–	–	–
Total liabilities and net assets	540.5	508.0	520.3	529.4	534.4	533.5	532.5	+12.2	(1.0)	–	–	–

Cash Flows

(Billions of Yen)

	FY2009	FY2010	FY2011				FY2012			
	1-12	1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12
	Full-year	Full-year	YTD	YTD	YTD	Full-year	YTD	YTD	YTD	Full-year
Net cash provided by (used in) operating activities	66.5	15.6	39.6	50.2	67.8	69.6	34.0	-	-	-
Net cash provided by (used in) investing activities	(20.3)	(20.2)	(0.8)	(3.7)	(6.4)	(15.1)	(8.8)	-	-	-
Net cash provided by (used in) financing activities	(22.3)	(23.1)	(13.2)	(13.2)	(24.3)	(24.6)	(11.1)	-	-	-
Effect of exchange rate changes on cash and cash equivalents	(0.1)	(1.7)	0.7	0.6	(0.7)	(0.6)	0.7	-	-	-
Net increase (decrease) in cash and cash equivalents	23.8	(29.3)	26.4	34.0	36.5	29.3	14.9	-	-	-
Cash and cash equivalents at beginning of period	70.7	94.5	65.1	65.1	65.1	65.1	94.5	-	-	-
Cash and cash equivalents at end of period	94.5	65.1	91.6	99.1	101.7	94.5	109.4	-	-	-

Performance Indicators

	FY2009	FY2010	FY2011				FY2012				Forecast
	1-12	1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12	FY2012
	As of Dec. 31	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Dec. 31
Net income per share (Basic)	104.00yen	76.14yen	9.17yen	31.40yen	49.85yen	64.75yen	17.17yen	-	-	-	90.04yen
Net income per share (Fully diluted) *1	103.98yen	76.12yen	9.17yen	31.39yen	49.84yen	64.72yen	17.16yen	-	-	-	-
Ratio of net income to shareholders' equity *2	13.7%	9.4%	1.1%	3.8%	6.0%	7.8%	2.0%	-	-	-	-
Ratio of ordinary income to total assets *2	17.7%	12.4%	3.2%	7.0%	9.8%	12.2%	3.1%	-	-	-	-
Net assets per share	794.51yen	821.87yen	810.62yen	832.45yen	826.39yen	839.50yen	842.68yen	-	-	-	-
Equity ratio	80.0%	88.0%	84.8%	85.6%	84.2%	85.6%	86.1%	-	-	-	-
Dividend per share (Annual)	40yen	40yen				40yen					40yen
Dividend per share (Interim)	17yen	17yen				20yen					20yen
Dividend payout ratio (Consolidated)	38.5%	61.8%				61.8%					44.4%

Notes: 1. "Accounting Standard for Earnings Per Share" (Accounting Standards Board of Japan (ASBJ) Statement No. 2, revised on June 30, 2010) and "Guidance on Accounting Standard for Earnings Per Share" (ASBJ Guidance No. 4, revised on June 30, 2010) are not applied to the amounts for FY2009, FY2010 and FY2011.
2. Quarterly (year-to-date) Ratio of net income to shareholders' equity and Ratio of ordinary income to total assets are not annualized.

Number of Employees

	FY2009	FY2010	FY2011				FY2012				Forecast
	1-12	1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12	FY2012
	As of Dec. 31	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Dec. 31
Number of employees	6,485	6,709	6,635	6,818	6,812	6,779	6,760	-	-	-	6,900

Note: Number of employees doesn't includes staff seconded to companies outside the Group.

Capital Expenditures

(Billions of Yen)

	FY2009	FY2010	FY2011				FY2012				Forecast
	1-12	1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12	FY2012
	Full-year	Full-year	YTD	YTD	YTD	Full-year	YTD	YTD	YTD	Full-year	Full-year
Capital expenditures	14.6	12.7	1.4	4.6	6.4	11.9	1.2	-	-	-	18.0
Depreciation	19.5	18.0	3.8	7.2	11.4	15.9	3.5	-	-	-	16.0

Development pipeline (as of April 24, 2012)

Development code	Indication # Additional indication	Stage (date)	Generic name Product name Dosage form	Origin Overseas name (Collaborator)	Mode of Action
<u>Oncology</u>					
RG435	Gastric cancer #	Phase III	bevacizumab Avastin Injection	Roche Avastin	Anti-VEGF(Vascular Endothelial Growth Factor) humanized monoclonal antibody
	Breast cancer (adjuvant) #	Phase III Multinational study			
	Glioblastoma #	Phase III Multinational study			
	Glioblastoma (relapsed) #	Phase II			
RG1273	Breast cancer	Phase III Multinational study	pertuzumab Injection	Roche	Humanized HER dimerization inhibitory monoclonal antibody
	Breast cancer (adjuvant)	Phase III Multinational study			
RG3502	Breast cancer	Phase III Multinational study	trastuzumab emtansine Injection	Roche	HER2 antibody-drug conjugate (T-DM1)
GA101 (RG7159)	Indolent NHL	Phase III Multinational study	obinutuzumab Injection	Roche	Humanized anti-CD20 monoclonal antibody
	Aggressive NHL	Phase III Multinational study			
GC33 (RG7686)	Liver cancer	Phase II Multinational study	Injection	In-house (Roche)	Humanized anti-Glypican-3 monoclonal antibody
RG1415	Non-small cell lung cancer (1st line) #	Phase II	erlotinib HCl Tarceva Oral	Roche/OSI Tarceva	EGFR tyrosine kinase inhibitor
MRA	Pancreatic cancer #	Phase I / II	tocilizumab Actemra Injection	In-house	Humanized anti-human IL-6 receptor monoclonal antibody
AF802	Non-small cell lung cancer	Phase I / II	Oral	In-house	ALK inhibitor

Development code	Indication # Additional indication	Stage (date)	Generic name Product name Dosage form	Origin Overseas name (Collaborator)	Mode of Action
WT4869	Myelodysplastic syndromes	Phase I / II	Injection	In-house / Dainippon Sumitomo Pharma	WT1 peptide cancer vaccine
	Solid tumors	Phase I			
CIF (RG7167)	Solid tumors	Phase I	Oral	In-house (Roche)	MEK inhibitor
		Phase I Overseas			
CKI27 (RG7304)	Solid tumors	Phase I	Oral	In-house (Roche)	Raf and MEK dual inhibitor
		Phase I Overseas			
PA799	Solid tumors	Phase I Overseas	Oral	In-house	PI3K class I inhibitor
RG3638	Non-small cell lung cancer	Phase I	onarutuzumab Injection	Roche	Humanized anti–Met antibody (MetMAb)
<u>Bone and Joint Diseases</u>					
NRD101	Enthesopathy (Lateral epicondylitis, Patellar tendinitis, Achilles tendinopathy, Plantar fasciitis)	Phase III	sodium hyaluronate Suvenyl Injection	In-house	Sodium hyaluronate
RG484	Osteoporosis	Phase II / III	ibandronate sodium hydrate Injection	Roche Boniva (US) / Bonviva (EU) (Taisho Pharmaceutical)	Bisphosphonate
		Phase II	ibandronate sodium hydrate Oral		
<u>Autoimmune Diseases</u>					
MRA	Rheumatoid arthritis (new formulation: subcutaneous injection)	Filed (12/03)	tocilizumab Actemra / RoActemra(EU) Injection	In-house (Roche)	Humanized anti-human IL-6 receptor monoclonal antibody
		Phase III Overseas			
SA237	Rheumatoid arthritis	Phase I	Injection	In-house	Humanized anti-human IL-6 receptor monoclonal antibody

Development code	Indication # Additional indication	Stage (date)	Generic name Product name Dosage form	Origin Overseas name (Collaborator)	Mode of Action
<u>Diabetes Mellitus</u>					
CSG452	Type II diabetes	Phase III	tofogliflozin hydrate Oral	In-house	SGLT2 inhibitor
<u>Central Nervous System</u>					
RG1678	Schizophrenia	Phase III Multinational study	bitopertin Oral	Roche	Glycine reuptake inhibitor
RG7090	Major depressive disorder	Phase II Multinational study	Oral	Roche	mGluR5 antagonist
RG1450	Alzheimer's disease	Phase I	gantenerumab Injection	Roche/Morphosys	Human anti-amyloid-beta monoclonal antibody
<u>Respiratory Diseases</u>					
RG3637	Asthma	Phase I	lebrikizumab Injection	Roche	Humanized anti-IL-13 antibody

Changes from the last announcement on February 1, 2012

Oncology

- GC33 (RG7686) Phase I → Phase II multinational study (Liver cancer)
- RG1273 Phase III multinational study (Breast cancer (adjuvant): Starting development)

Autoimmune Diseases

- MRA Phase III → Filed (Rheumatoid arthritis (New formulation: subcutaneous formulation))

Central Nervous System

- RG7090 Phase I (overseas) → Phase II multinational study (Major depressive disorder)

R&D Activities (Jan. 1, 2012 – Apr. 24, 2012)

As for clinical development activities in Japan, the Company saw progress as described below:

Oncology

- In March 2012, we started a Phase II multinational study (expected indication: liver cancer) for a humanized anti-Glypican-3 monoclonal antibody, GC33 (RG7686).
- In April 2012, we started a Phase III multinational study (expected indication: breast cancer (adjuvant) for a humanized HER dimerization inhibitory monoclonal antibody, RG1273.
- The application for an additional indication of a recombinant human erythropoietin, EPOCH (product name: Epogin) (expected indication: chemotherapy induced anemia) was removed from the pipeline chart following the receipt of the unapproval letter in October 2011. The company will continue to review options for resubmission.

Autoimmune diseases

- In March 2012, we filed an application for an additional indication of a humanized anti-human IL-6 receptor monoclonal antibody, MRA (product name: Actemra/ RoActemra) for rheumatoid arthritis (new formulation: subcutaneous formulation.)

Central Nervous System

- In April 2012, we decided to participate in the Phase II multinational study (expected indication: major depressive disorder) conducted by Roche for an mGluR5 antagonist, RG7090.

Also, as for development activities overseas, the Company saw progress as described below:

- In April 2012, we obtained an approval for a humanized anti-human IL-6 receptor monoclonal antibody, MRA (product name: Actemra/ RoActemra), for rheumatoid arthritis in Korea.

Major clinical trials in oncology field currently running in Japan

Theme	Expected Indication	Regimen	Stage	Planned Filing Date
RG435 (bevacizumab) Avastin	Breast cancer (adjuvant)	standard chemotherapy ± RG435	BEATRICE study Phase III multinational study	2014
	Glioblastoma (1st line)	temozolomide ± RG435	AVAglio study Phase III multinational study	2014
	Glioblastoma (relapsed)	RG435	Phase II	2014
RG1415 (erlotinib HCL) Tarceva	Non-small cell lung cancer (1st line)	RG1415	Phase II	2012
RG1273 (pertuzumab)	Breast cancer (1st line)	RG597 + docetaxel ± RG1273	CLEOPATRA study Phase III multinational study	2012
	Breast cancer (adjuvant)	RG597 + chemotherapy ± RG1273	APHINITY study Phase III multinational study	Post 2015
RG3502 (trastuzumab emtansine)	Breast cancer (1st line)	RG3502 ± RG1273	MARIANNE study Phase III multinational study	2013
	Breast cancer (2nd line)	RG3502	Phase II	2013
GA101/ RG7159 (obinutuzumab)	Indolent NHL	GA101 + chemotherapy vs rituximab + chemotherapy (G-chemo vs R-chemo)	GALLIUM study Phase III multinational study	Post 2015
	Aggressive NHL	GA101 + CHOP vs rituximab + chemotherapy (G-CHOP vs R-CHOP)	GOYA study Phase III multinational study	Post 2015